


FORM PTO-1390 (Modified) (REV 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		<b>040283-0196</b>	
		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/009,567	
INTERNATIONAL APPLICATION NO. PCT/GB00/03008	INTERNATIONAL FILING DATE 08/04/2000	PRIORITY DATE CLAIMED 08/11/1999	
<b>TITLE OF INVENTION</b> Condensed Indoline Derivatives and their use as 5HT, in particular 5HT2C, Receptor Ligands			
<b>APPLICANT(S) FOR DO/EO/US</b> Jonathan Richard Anthony ROFFEY, James Edward Paul DAVIDSON, Howard Langham MANSELL, Richard John HAMLYN and David Reginald ADAMS			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
1. <input type="checkbox"/>	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.		
2. <input checked="" type="checkbox"/>	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.		
3. <input type="checkbox"/>	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).		
4. <input type="checkbox"/>	A proper Demand for International Preliminary Examination was made by the 19 <sup>th</sup> month from the earliest claimed priority date.		
5. <input type="checkbox"/>	A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)		
6. <input type="checkbox"/>	A translation of the International Application into English (35 U.S.C. 371(c)(2)).		
7. <input type="checkbox"/>	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input type="checkbox"/> have not been made and will not be made.		
8. <input type="checkbox"/>	A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).		
9. <input checked="" type="checkbox"/>	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) (5 pgs.).		
10. <input type="checkbox"/>	A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).		
11. <input checked="" type="checkbox"/>	Applicant claims small entity status under 37 CFR 1.27.		
Items 12. to 17. below concern other document(s) or information included:			
12. <input checked="" type="checkbox"/>	An Information Disclosure Statement under 37 CFR 1.97 and 1.98 with Form PTO/SB/08 and 11 references.		
13. <input type="checkbox"/>	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.		
14. <input type="checkbox"/>	A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.		
15. <input type="checkbox"/>	A substitute specification.		
16. <input type="checkbox"/>	A change of power of attorney and/or address letter.		
17. <input type="checkbox"/>	Other items or information: Notice of Missing Requirements (2 pgs.), letter regarding sequence listing.		

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.50 10/009,567		INTERNATIONAL APPLICATION NO. PCT/GB00/03008		ATTORNEY'S DOCKET NUMBER 040283-0196	
18. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY	
Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO.....\$890.00  International preliminary examination fee paid to USPTO (37 CFR 1.482).....\$710.00  No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2) .....\$740.00  Neither international preliminary examination fee (37 CFR 1.482) nor International search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$1,040.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) .....\$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$0.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 Months from the earliest claimed priority date (37 CFR 1.492(e))				\$130.00	
Claims	Number Filed	Included in Basic Fee	Extra Claims		Rate
Total Claims	-	20	= 0	×	\$18.00
Independent Claims	-	3	= 0	×	\$84.00
Multiple dependent claim(s) (if applicable)				\$280.00	
TOTAL OF ABOVE CALCULATIONS =				\$130.00	
Reduction by ½ for filing by small entity, if applicable.				\$65.00	
SUBTOTAL =				\$65.00	
Processing fee of \$130.00 for furnishing English translation later the 20 months from the earliest claimed priority date (37 CFR 1.492(f). +  TOTAL NATIONAL FEE = \$65.00					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +  TOTAL FEES ENCLOSED = \$65.00					
				Amount to be: refunded \$	
				charged \$	
a. <input checked="" type="checkbox"/> A check in the amount of \$65.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>06-1447</u> in the amount of \$0.00 to the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>06-1447</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:  Foley & Lardner Washington Harbour 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5143					
 SIGNATURE <u>TM</u> <u>40,413</u> NAME <u>TODD J. BURNS</u> <u>fr</u> REGISTRATION NUMBER <u>38,011</u>					

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Jonathan Richard Anthony ROFFEY et al.

Title: Condensed Indoline Derivatives and their use as 5HT, in particular  
5HT2C, Receptor Ligands

Appl. No.: 10/009,567

Filing Date: 03/22/2002

Examiner: Unassigned

Art Unit: Unassigned

**LETTER REGARDING NOTIFICATION OF MISSING REQUIREMENTS**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

A Notification of Missing Requirements under 37 U.S.C. § 371 ("Notification") was mailed February 6, 2002. The Notification states, inter alia, that a sequence listing must be provided for the nucleotide and/or amino acid sequence disclosure contained in the application. The undersigned has reviewed the application and has found no nucleotide and/or amino acid sequence disclosed in the application. Accordingly, there is no sequence listing that can be provided.

In the event the PTO disagrees, applicants respectfully request that the PTO point out page number and line number where such nucleotide and/or amino acid sequence disclosure is contained.

Respectfully submitted,

By   
M. *Todd J. Burns*  
4/10, 2002

Date: April 5, 2002

FOLEY & LARDNER  
Washington Harbour  
3000 K Street, N.W., Suite 500  
Washington, D.C. 20007-5143  
Telephone: (202) 672-5583  
Facsimile: (202) 672-5399

for Todd J. Burns  
Attorney for Applicant  
Registration No. 38,011